Maryland Senate Bill SB757

Maryland 2025 Regular Session

• Introduced: 1/31/25
• Refer: 1/31/25
• Report Pass: 4/4/25
• Engrossed: 4/4/25
• Refer: 4/5/25

Caption

Disability and Life Insurance - Medical Information (Genetic Testing Protection Act)

Impact

The implications of SB757 are significant as it aims to fortify protections for individuals against potential biases in insurance practices. By preventing providers from considering genetic testing results when determining eligibility or rates for insurance policies, the bill protects individuals from being penalized for their genetic health predispositions. This measure supports a more equitable insurance framework and is designed to promote fair treatment among policyholders while safeguarding personal medical privacy.

Summary

Senate Bill 757, titled the Genetic Testing Protection Act, seeks to address the ethical implications of using genetic information in the life insurance and disability insurance sectors. The bill specifically prohibits insurance carriers from denying coverage, limiting benefits, or increasing premiums based on whether an individual has undergone genetic testing or possesses genetic information. It establishes that obtaining sensitive medical information without written consent is impermissible, ensuring that individuals are not unfairly discriminated against due to their genetic predispositions.

Sentiment

The sentiment regarding SB757 appears largely supportive among advocacy groups and individuals concerned about medical privacy rights, especially in context to genetic testing. Proponents argue that the bill is a necessary step toward enhancing consumer protections and ensuring that individuals are treated fairly regardless of their genetic background. However, there may be some contention from insurance industry representatives who worry about the potential impacts on risk assessment and pricing models, arguing that such restrictions could affect the overall sustainability of insurance products.

Contention

Key points of contention around SB757 involve the balance between protecting consumer rights and allowing insurance carriers the flexibility to assess risk appropriately. Opponents in the insurance community may argue that prohibiting the use of genetic information could hinder their ability to accurately set rates and provide sustainable policies. Supporters, however, insist that genetic predisposition should not be a basis for discrimination, emphasizing that the financial and health implications of genetic risks should not burden individuals seeking insurance coverage.